Across TCGA pan-cancer cohorts, HCRTR2 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of HCRTR2’s most consistent transcriptional readouts.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where HCRTR2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types HCRTR2 is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.
LSCC and COAD are the cancer types where HCRTR2 tumor–normal differential expression is most reproducible.